當(dāng)前位置：首頁(yè) SCI期刊 SCIE期刊醫(yī)學(xué) 中科院4區(qū) JCRQ4 期刊介紹(非官網(wǎng))

American Journal Of Clinical Oncology-cancer Clinical TrialsSCIE

國(guó)際簡(jiǎn)稱：AM J CLIN ONCOL-CANC 參考譯名：美國(guó)臨床腫瘤學(xué)雜志-癌癥臨床試驗(yàn)

中科院分區(qū)
4區(qū)
CiteScore分區(qū)
Q2
JCR分區(qū)
Q4

基本信息：: ISSN：0277-3732; E-ISSN：1537-453X; 是否OA：未開(kāi)放; 是否預(yù)警：否; TOP期刊：否

出版信息：: 出版地區(qū)：UNITED STATES; 出版商：Lippincott Williams and Wilkins Ltd.; 出版語(yǔ)言：English; 出版周期：Bimonthly; 出版年份：1982; 研究方向：醫(yī)學(xué)-腫瘤學(xué)

評(píng)價(jià)信息：: 影響因子：1.6; H-index：72; CiteScore指數(shù)：4.9; SJR指數(shù)：0.711; SNIP指數(shù)：0.576

發(fā)文數(shù)據(jù)：: Gold OA文章占比：9.84%; 研究類文章占比：70.13%; 年發(fā)文量：77; 自引率：0; 開(kāi)源占比：0.0552; 出版撤稿占比：0; 出版國(guó)人文章占比：0.04; OA被引用占比：0.0674...

投稿咨詢加急見(jiàn)刊

英文簡(jiǎn)介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見(jiàn)問(wèn)題

英文簡(jiǎn)介American Journal Of Clinical Oncology-cancer Clinical Trials期刊介紹

???????American Journal of Clinical Oncology is a multidisciplinary journal for cancer surgeons, radiation oncologists, medical oncologists, GYN oncologists, and pediatric oncologists.

The emphasis of AJCO is on combined modality multidisciplinary loco-regional management of cancer. The journal also gives emphasis to translational research, outcome studies, and cost utility analyses, and includes opinion pieces and review articles.

The editorial board includes a large number of distinguished surgeons, radiation oncologists, medical oncologists, GYN oncologists, pediatric oncologists, and others who are internationally recognized for expertise in their fields.

期刊簡(jiǎn)介American Journal Of Clinical Oncology-cancer Clinical Trials期刊介紹

《American Journal Of Clinical Oncology-cancer Clinical Trials》自1982出版以來(lái)，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見(jiàn)解，或?qū)彶槎嗄陙?lái)某個(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫(kù)SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間：偏慢,4-8周
醫(yī)學(xué)
ONCOLOGY
SCIE
中科院4區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）American Journal Of Clinical Oncology-cancer Clinical Trials Cite Score數(shù)據(jù)

CiteScore：4.9
SJR：0.711
SNIP：0.576

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Oncology	Q2	176 / 404	56%
大類：Medicine 小類：Cancer Research	Q3	137 / 230	40%

CiteScore 是由Elsevier(愛(ài)思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫(kù)中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過(guò)影響因子(IF)這一單一指標(biāo)來(lái)評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)American Journal Of Clinical Oncology-cancer Clinical Trials 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：否 Top期刊：否

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	4區(qū)	ONCOLOGY 腫瘤學(xué)	4區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國(guó)際、國(guó)內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國(guó)科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國(guó)際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國(guó)各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開(kāi)始，這個(gè)分區(qū)只是為了方便圖書(shū)管理及圖書(shū)情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)American Journal Of Clinical Oncology-cancer Clinical Trials JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：ONCOLOGY	SCIE	Q4	253 / 322	21.6%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：ONCOLOGY	SCIE	Q3	220 / 322	31.83%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問(wèn)題的。因此，JCR將期刊按照學(xué)科門(mén)類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

發(fā)文數(shù)據(jù)

2023-2024 年國(guó)家/地區(qū)發(fā)文量統(tǒng)計(jì)

國(guó)家/地區(qū)數(shù)量
USA382
Canada42
Italy25
CHINA MAINLAND23
South Korea12
Israel10
France9
England8
Japan8
Brazil7

本刊中國(guó)學(xué)者近年發(fā)表論文

1、Therapeutic Evaluation of Induction Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma With Low-risk N Stage A Multicenter Retrospective Study From Nonendemic Region of China
Author: Zang, Jian; Li, Yan; Liu, Qiufang; Zhu, Yong; Luo, Shanquan; Li, Xiaohua; Wang, Jianhua; Hou, Bingxin; Su, Ning; Zhao, Lina; Shi, Mei

Journal: AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. 2023; Vol. 46, Issue 5, pp. 206-212. DOI: 10.1097/COC.0000000000000995
2、A Scoring System to Select the Candidates for Adjuvant Chemotherapy Alone in High-Risk Early-Stage Cervical Cancer Patients With Pelvic Lymph Node Metastases After Surgery
Author: Yang, Xi-Lin; Yang, Feng-Leng; Wang, Na; Zhang, Yue-Er; Kou, Ling-Na; Wu, Da-Jun; Luo, Yi

Journal: AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. 2023; Vol. 46, Issue 5, pp. 219-224. DOI: 10.1097/COC.0000000000000996
3、A Preliminary Study of Immediate Intraperitoneal Chemotherapy for Stage III Colorectal Cancer
Author: Huang, Kai-Xin; Pan, Yi-fei; Dai, Rui-shuai; Xu, Ling-Sha; Zhu, Bo-Wang; Zhang, Xiao-Dong; Hu, Yi-wang

Journal: AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. 2023; Vol. 46, Issue 5, pp. 193-198. DOI: 10.1097/COC.0000000000000980
4、The Role of Signaling Pathways in Pancreatic Cancer Targeted Therapy
Author: Zhuo, Fangfang; Luo, Shuang; He, Wei; Feng, Zhanhui; Hu, Ya'nan; Xu, Jingxia; Wang, Zejun; Xu, Jianwei

Journal: AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. 2023; Vol. 46, Issue 3, pp. 121-128. DOI: 10.1097/COC.0000000000000979
5、Prognostic Value of the Cutoffs for HALP in Endometrial Cancer
Author: Wang, Jinyu; Jiang, Peng; Huang, Yuzhen; Tu, Yuan; Zhou, Qian; Li, Ning; Kong, Wei; Yuan, Rui

Journal: AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. 2023; Vol. 46, Issue 3, pp. 107-113. DOI: 10.1097/COC.0000000000000977
6、Update on Chemoresistance Mechanisms to First-Line Chemotherapy for Gallbladder Cancer and Potential Reversal Strategies
Author: Lai, Jinbao; Yang, Songlin; Lin, Zhuying; Huang, Wenwen; Li, Xiao; Li, Ruhong; Tan, Jing; Wang, Wenju

Journal: AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. 2023; Vol. 46, Issue 4, pp. 131-141. DOI: 10.1097/COC.0000000000000989
7、Efficacy and Prognostic Factors of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer
Author: Hu, Yu-xiong; Guo, Li-jing; Lin, Meng-qing; Lin, Qing-yu

Journal: AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. 2023; Vol. 46, Issue 4, pp. 161-166. DOI: 10.1097/COC.0000000000000985
8、The Impact of Concomitant Proton Pump Inhibitors Therapy on Clinical Outcome of Cancer Patients Treated With Immune Checkpoint Inhibitors A Meta-analysis
Author: Cao, Xing; Wang, Yafei; Huang, Wei; Li, Panyun; Guo, Chongjie; Li, Yuhui

Journal: AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. 2023; Vol. 46, Issue 4, pp. 142-149. DOI: 10.1097/COC.0000000000000991